An Open-Label, Multicenter, Evaluation of the Long-Term Safety and Efficacy of Recombinant Human Coagulation Factor IX Fusion Protein (rFIXFc) in the Prevention and Treatment of Bleeding Episodes in Previously Treated Subjects With Hemophilia B

Trial Profile

An Open-Label, Multicenter, Evaluation of the Long-Term Safety and Efficacy of Recombinant Human Coagulation Factor IX Fusion Protein (rFIXFc) in the Prevention and Treatment of Bleeding Episodes in Previously Treated Subjects With Hemophilia B

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Feb 2018

At a glance

  • Drugs Eftrenonacog alfa (Primary)
  • Indications Haemophilia B
  • Focus Adverse reactions; Registrational
  • Acronyms B-YOND
  • Sponsors Biogen; Bioverativ
  • Most Recent Events

    • 20 Dec 2017 Status changed from active, no longer recruiting to completed.
    • 12 Dec 2017 Results of B-LONG and B-YOND studies assessing clinical outcomes, presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
    • 11 Dec 2017 Results published in the Bioverativ media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top